Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The staphylococcal peptidoglycan pentaglycine cross-bridge is a specialized structural component of the cell wall in Staphylococcus aureus and certain other staphylococci (Schleifer and Kandler, 1972). It is composed of five glycine residues that form a bridge between the L-lysine of one peptidoglycan stem peptide and the D-alanine of another, facilitating extensive cross-linking of the glycan strands (Rohrer et al., 1999). This structure is essential for maintaining the mechanical integrity and osmotic stability of the bacterial cell. Because this specific pentaglycine motif is unique to staphylococci, it represents a highly selective target for antimicrobial therapy. The enzyme lysostaphin, a glycylglycine endopeptidase, specifically cleaves these bridges, leading to rapid bacterial lysis and death (Bastos et al., 2010). Research also focuses on inhibiting the Fem (factor essential for methicillin resistance) protein family, which catalyzes the assembly of the pentaglycine bridge, as a strategy to restore antibiotic sensitivity in resistant strains (Ehlert et al., 1997).
Lysostaphin acts as a glycylglycine endopeptidase that specifically cleaves the pentaglycine cross-bridges, leading to bacterial cell lysis (Bastos et al., 2010). Fem inhibitors block the enzymes responsible for the sequential addition of glycine residues to the peptidoglycan precursor (Rohrer et al., 1999).
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Staphylococcal peptidoglycan pentaglycine cross-bridge ((Gly)5 bridge).